文献速递炎症性肠病

补充1-蔗果三糖对轻中度溃疡性结肠炎患者的疗效:一项随机、双盲、安慰剂对照的先导研究

Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double-blind, placebo-controlled pilot study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-01-16

该随机双盲安慰剂对照先导试验将40例轻中度活动性溃疡性结肠炎患者随机分为1-蔗果三糖组(N=20)和安慰剂(麦芽糖)组(N=20),在标准治疗基础上口服干预8周。第8周1-蔗果三糖组临床活动指数显著低于安慰剂组(3.8±2.7 vs. 5.6±2.1,p=0.026),临床缓解率更高(55% vs. 20%,p=0.048),但内镜严重指数无显著差异(2.8±1.6 vs. 3.5±1.6,p=0.145)。

要点

  • 1-蔗果三糖组第8周临床活动指数显著低于安慰剂组(3.8±2.7 vs. 5.6±2.1,p=0.026)。
  • 临床缓解率1-蔗果三糖组55% vs. 安慰剂组20%(p=0.048),应答率60% vs. 25%(p=0.054)。
  • 内镜严重指数第8周两组无显著差异(2.8±1.6 vs. 3.5±1.6,p=0.145),不良事件发生率相当。

核心结论

  • 口服1-蔗果三糖耐受性良好,并通过调节肠道菌群对轻中度溃疡性结肠炎患者提供临床改善。

研究设计与样本

  • 随机、双盲、安慰剂对照先导试验,40例轻中度活动性溃疡性结肠炎患者随机接受1-蔗果三糖(N=20)或安慰剂麦芽糖(N=20)口服8周,均附加标准治疗。

主要发现

  • 第8周临床活动指数1-蔗果三糖组显著低于安慰剂组(3.8±2.7 vs. 5.6±2.1,p=0.026)。
  • 临床缓解率1-蔗果三糖组高于安慰剂组(55% vs. 20%,p=0.048);应答率1-蔗果三糖组60% vs. 安慰剂组25%(p=0.054)。
  • 第8周内镜严重指数两组无显著差异(2.8±1.6 vs. 3.5±1.6,p=0.145)。
  • 粪便分析显示1-蔗果三糖组α多样性显著降低,包括瘤胃球菌属gnavus群在内的多种细菌相对丰度下降;短链脂肪酸水平两组无显著差异。
  • 不良事件发生率两组相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ulcerative colitis involves an excessive immune response to intestinal bacteria. Whether administering prebiotic 1-kestose is effective for active ulcerative colitis remains controversial. AIMS: This randomised, double-blind, placebo-controlled pilot trial investigated the efficacy of 1-kestose against active ulcerative colitis. METHODS: Forty patients with mild to moderate active ulcerative colitis were randomly treated with 1-kestose (N = 20) or placebo (maltose, N = 20) orally for 8 weeks in addition to the standard treatment. The Lichtiger clinical activity index and Ulcerative Colitis Endoscopic Index of Severity were determined. Faecal samples were analysed to evaluate the gut microbiome and metabolites. RESULTS: The clinical activity index at week 8 was significantly lower in the 1-kestose group than in the placebo group (3.8 ± 2.7 vs. 5.6 ± 2.1, p = 0.026). Clinical remission and response rates were higher in the 1-kestose group than in the placebo group (remission: 55% vs. 20%, p = 0.048; response: 60% vs. 25%, p = 0.054). The Ulcerative Colitis Endoscopic Index of Severity at week 8 was not significantly different (2.8 ± 1.6 vs. 3.5 ± 1.6, p = 0.145). Faecal analysis showed significantly reduced alpha-diversity in the 1-kestose group, with a decreased relative abundance of several bacteria, including Ruminococcus gnavus group. The short-chain fatty acid levels were not significantly different between the groups. The incidence of adverse events was comparable between the groups. DISCUSSION: Oral 1-kestose is well tolerated and provides clinical improvement for patients with mild to moderate ulcerative colitis through modulation of the gut microbiome.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ikegami S, Nakamura M, Honda T, et al. Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double-blind, placebo-controlled pilot study. Aliment Pharmacol Ther. 2023. PMID: 36644995. doi:10.1111/apt.17387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。